Focus New

Update on the Latest Anti-SARS-CoV-2 Molecules

The emergence of SARS-CoV-2 has precipitated an unprecedented effort by the scientific community to find and develop potential therapeutics and vaccines for this new virus to halt the ongoing pandemic’s onslaught. Fortunately, the SARS-CoV-2 genome is highly homologous to SARS-CoV, which caused the SARS outbreak in 2003. Thus, the research on the original SARS virus …

Update on the Latest Anti-SARS-CoV-2 Molecules Read More »

REV-ERB agonists and Cancer

Researchers at the Salk Institute, the University of California, and the University of Texas have identified a potential new class of cancer therapeutics. REV-ERBs are nuclear hormone receptors that are critical components of the circadian clock, the body’s mechanism for establishing daily rhythms in cellular proliferation, metabolism, and other essential processes.  Dysregulation of this system is …

REV-ERB agonists and Cancer Read More »

SHP099 targets ALK inhibitor resistant cancer

Multiple cellular pathways can lead to acquired resistance to ALK inhibitors.  A common pathway is activation of alternate kinase pathways, including EGFR, KIT, SRC, and IGF1R to maintain activation of downstream ERK and/or PI3K-AKT signaling.  Addition of inhibitors to these pathways is a viable response, but not optimal due to the presence of multiple alternatives. Dardaei …

SHP099 targets ALK inhibitor resistant cancer Read More »

A potential new role for RIP1 kinase

Researchers have discovered that inhibition of RIP1 kinase blocks the progression of multiple sclerosis in an immune-induced demyelination mouse model (EAE) but not a chemically-induced one (CPZ). RIPA-56 (Focus Biomolecules Cat# 10-4611) blocked disease progression at a step of monocyte elevation downstream of T-cell activation and myelin-specific antibody generation but upstream of blood-brain barrier breakdown. This …

A potential new role for RIP1 kinase Read More »